A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Jiyun LeeSehhoon ParkHyun Ae JungSe-Hoon LeeSeyoung SeoSung-Bae KimJi-Won KimKeun-Wook LeeEun Joo KangJu Won KimYoon Ji ChoiByoung-Yong ShimHo-Jung AnLee Chun ParkSeong Hoon ShinJae-Joon KimSo Yeon OhMin Kyoung KimMyung-Ju AhnPublished in: Cancer (2023)
Salivary duct carcinoma (SDC) is uncommon but is the most aggressive subtype of salivary gland carcinomas. SDC shares morphological and histological similarities with invasive ductal carcinoma of breast, which led to an investigation of hormonal receptor and human epidermal growth factor receptor 2 (HER2)/neu expression status in SDC. In this study, patients with HER2-positive SDC were enrolled and treated with combination of docetaxel-polymeric micelle and trastuzumab-pkrb. Promising antitumor activities were shown with objective response rate of 69.8%, disease control rate of 93.0%, median progression-free survival of 7.9 months, median duration of response of 6.7 months, and median overall survival of 23.3 months.
Keyphrases
- epidermal growth factor receptor
- free survival
- combination therapy
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- poor prognosis
- high grade
- squamous cell carcinoma
- locally advanced
- small cell lung cancer
- air pollution
- drug delivery
- radiation therapy
- heavy metals
- particulate matter
- binding protein
- type diabetes
- insulin resistance
- metastatic breast cancer
- rectal cancer
- polycystic ovary syndrome
- skeletal muscle
- water soluble
- risk assessment
- drug release
- pluripotent stem cells